Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR. On the whole, the ...

An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ...

Tricuspid valve (TV) disease most often occurs secondary to left-sided heart disease, particularly mitral valve (MV) regurgitation or stenosis. Appropriate treatment, even when TV regurgitation is ...

LONDON, England—There are more positive signs that current-generation transcatheter valves, originally designed to treat tricuspid aortic stenosis (AS), do just fine in the setting of bicuspid disease ...

Tricuspid valve regurgitation (TR) occurs when the leaflets of the tricuspid valve fail to coapt fully during right ventricular systole, permitting retrograde blood flow into the right atrium. This ...

Please provide your email address to receive an email when new articles are posted on . In patients who had mitral valve surgery but also tricuspid regurgitation or tricuspid annular dilation, ...

Addressing moderate or lesser tricuspid regurgitation (TR) during mitral valve surgery improved outcomes, largely by halting progression of the leaky tricuspid, a randomized trial from the ...

Real-world data accumulated in Europe outside of a clinical trial support both the safety and the benefit of two transcatheter edge-to-edge (TEER) devices designed specifically for the treatment of ...

Tricuspid regurgitation is when blood flows backwards through the tricuspid valve because it does not close properly during systole. It can be caused by a problem with the valve itself (primary). But ...

The tricuspid valve sits between the right atrium and right ventricle of the heart. Tricuspid regurgitation occurs because the tricuspid valve does not close properly during systole. It can result in ...

Right ventricular dysfunction (RVD) is prevalent in 41.7 percent of patients with heart failure with preserved ejection ...